Presentation is loading. Please wait.

Presentation is loading. Please wait.

Translating Emerging HIV Data Into Clinical Practice

Published byDewi Kusuma Modified over 6 years ago

Similar presentations

Presentation on theme: "Translating Emerging HIV Data Into Clinical Practice"— Presentation transcript:

1 Translating Emerging HIV Data Into Clinical Practice

2

3

4 ART and the Search for an HIV Cure

5 The Mississippi Child: An Update on A Presumptive Cure With Early ART

6 “Kick and Kill”: Reducing the Latent HIV Reservoir

7 PrEP: Implementation, Management Considerations, and Identifying At-Risk Populations

8 PrEP US Demo Project: Baseline Risk Behaviors and PrEP Acceptance

9 iPrEx OLE Study: Perfect Adherence Not Necessary for Effective PrEP

10 ANRS Ipergay Study: High Rate of Adherence to Intermittent Oral PrEP

11 HIV Management: Regimen Simplification and Options for Resistant Variants

12 OLE Study: Dual Therapy With LPV/r + 3TC Noninferior to LPV/r + 2 NRTIs

13 SALT Study: Switch to ATV/r + 3TC Noninferior to ATV/r + 2 NRTIs

14 HARNESS Study: Increased Virologic Rebound ATV/r + RAL vs ATV/r + TDF/FTC

15 DTG-based Regimens Active in Patients INSTI-Naïve, NRTI-Resistant

16 Treating the Patient With HIV/HCV Coinfection

17 PHOTON-2: SOF + RBV Yields High SVR12 in HIV/HCV Coinfection

18 TURQUOISE-I: Novel 3 Drug Regimen + RBV Safe and Efficacious for HIV/HCV Coinfection

19 DTG-Based Regimens’ Comparable Results in HIV/HCV Coinfected vs HIV Monoinfected

20 Abbreviations

21 Abbreviations (cont)

22 Abbreviations (cont)

23 References

24 References (cont)

25 References (cont)

Download ppt "Translating Emerging HIV Data Into Clinical Practice"

Similar presentations

Comparison of INSTI vs PI  FLAMINGO  GS-236-0103  ACTG A5257.

Comparison of INSTI vs PI  FLAMINGO  GS  ACTG A5257.
Switch to TDF/FTC/RPV - SPIRIT Study. SPIRIT study: switch PI/r + 2 NRTI to TDF/FTC/RPV STR  Design TDF/FTC/RPV STR 24 weeks 48 weeks Primary Endpoint.

Switch to TDF/FTC/RPV - SPIRIT Study. SPIRIT study: switch PI/r + 2 NRTI to TDF/FTC/RPV STR  Design TDF/FTC/RPV STR 24 weeks 48 weeks Primary Endpoint.
Switch to ATV/r + RAL  HARNESS Study. ATV/r 300/100 mg qd + TDF/FTC N = 37 N = 72 ATV/r 300/100 mg qd + RAL 400 mg bid  Design Randomisation 2: 1 Open-label.

Switch to ATV/r + RAL  HARNESS Study. ATV/r 300/100 mg qd + TDF/FTC N = 37 N = 72 ATV/r 300/100 mg qd + RAL 400 mg bid  Design Randomisation 2: 1 Open-label.
Comparison of PI vs PI  ATV vs ATV/r BMS 089  LPV/r mono vs LPV/r + ZDV/3TC MONARK  LPV/r QD vs BID M02-418 M05-730 A5073  LPV/r + 3TC vs LPV/r + 2.

Comparison of PI vs PI  ATV vs ATV/r BMS 089  LPV/r mono vs LPV/r + ZDV/3TC MONARK  LPV/r QD vs BID M M A5073  LPV/r + 3TC vs LPV/r + 2.
Switch to TDF/FTC/RPV  SPIRIT Study. SPIRIT study: Switch PI/r + 2 NRTI to TDF/FTC/RPV TDF/FTC/RPV STR 24 weeks 48 weeks Primary Endpoint Secondary Endpoint.

Switch to TDF/FTC/RPV  SPIRIT Study. SPIRIT study: Switch PI/r + 2 NRTI to TDF/FTC/RPV TDF/FTC/RPV STR 24 weeks 48 weeks Primary Endpoint Secondary Endpoint.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*

Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*
When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.

When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.
Switch to ATV/r-containing regimen  ATAZIP. Mallolas J, JAIDS 2009;51:29-36 ATAZIP ATAZIP Study: Switch LPV/r to ATV/r  Design  Endpoints –Primary:

Switch to ATV/r-containing regimen  ATAZIP. Mallolas J, JAIDS 2009;51:29-36 ATAZIP ATAZIP Study: Switch LPV/r to ATV/r  Design  Endpoints –Primary:
Switch to ATV/r monotherapy  ATARITMO  Swedish Study  ACTG A5201  OREY  MODAt Study.

Switch to ATV/r monotherapy  ATARITMO  Swedish Study  ACTG A5201  OREY  MODAt Study.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
ALLY-2  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotype 1 treated for 12 weeks DCV + SOF 400 mg QD DCV + SOF.

ALLY-2  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml), with 95% CI, in treatment-naïve genotype 1 treated for 12 weeks DCV + SOF 400 mg QD DCV + SOF.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.

Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
Switch to ATV ± r-containing regimen  SWAN Study  SLOAT Study.

Switch to ATV ± r-containing regimen  SWAN Study  SLOAT Study.
Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014.

Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014.
Joel E. Gallant, MD, MPH Medical Director, Specialty Services Southwest CARE Center Santa Fe, New Mexico State-of-the-ART in Antiretroviral Management.

Joel E. Gallant, MD, MPH Medical Director, Specialty Services Southwest CARE Center Santa Fe, New Mexico State-of-the-ART in Antiretroviral Management.
NRTI-sparing  SPARTAN  PROGRESS  NEAT001/ANRS 143  MODERN.

NRTI-sparing  SPARTAN  PROGRESS  NEAT001/ANRS 143  MODERN.
David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California State of the Art in Hepatitis C Virus Infection.

David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California State of the Art in Hepatitis C Virus Infection.
Sulkowski M. Lancet 2015;385:1087-97 C-WORTHY  Design Randomisation* Open-label > 18 years HCV genotype 1, treatment naïve HCV RNA ≥ 10,000 IU/ml No cirrhosis.

Sulkowski M. Lancet 2015;385: C-WORTHY  Design Randomisation* Open-label > 18 years HCV genotype 1, treatment naïve HCV RNA ≥ 10,000 IU/ml No cirrhosis.

Similar presentations

Ads by Google